Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. The optimal dialysate calcium (Ca) content for hemodialysis has been classically fixed at 1.75 m. However, this dialysate Ca concentration (dCa) with its positive intradialytic Ca balance combined with the use of CaCO3 as a phosphate binder may result in hypercalcemia. To prevent or treat hypercalcemia, a decrease in dCa has been proposed. In the present study both the acute and the long-term effects of lowering dCa were assessed. Additionally, given the results obtained after one year with low dCa the effectiveness of i.v. la vitamin D3 in lowering PTH serum levels in two groups of patients dialyzed with different dCa was also studied. (a) Ca kinetics during hemodialysis (HD) and on line hemodiafiltration (HDF) were studied in a group of nine stable patients who were sequentially treated with 1.75, 1.5 and 1.25 mM dCa. Dialysate was the same but for the dCa which was lowered stepwise. Na, K, tCa, ionized Ca (iCa), proteins, phosphate and pH were measured from blood inlet and outlet and dialysate outlet at the start, one hour, two hours and after the treatments. At the same time weight, blood pressure and heart rate were recorded. The sieving of iCa was significantly different in HDF versus HD (F = 6.73; P < 0.01); intravenous infusion of 18 liters of filtered ultrapure dialysate compensated the Ca loss due to the convective component of HDF, as iCa was similar at the blood inlet in HD and HDF in the three dCa tested (F = 2.59; NS). Intradialytic iCa kinetics measured in the blood inlet were significantly different with different dCa (P < 0.001 for 1,75 mM vs. 1.5 mm and P < 0.001 for 1.5 m vs. 1.25 mM). A significant increase in post-dialysis iCa was observed with dCa of 1.75 and 1.5 while no modification was observed with 1.25 mM dCa. (b) Regarding long-term effects of lowering dCa, seven of the nine patients acutely studied were followed for a one year period after changing from dCa = 1.5 to dCa = 1.25 ms. A control group of six patients was maintained with dCa = 1.5 for the same period of time and with the same treatment schedule but for dCa. Total Ca, phosphate and alkaline phosphatase were assessed monthly, and phosphate binders and oral vitamin D derivative doses were adapted accordingly. Intact PTH was determined quarterly.
Osteoarticular disease is a major concern in hemodialysis patients. The known pathogenic factors for bone disease in this population are multiple and interrelated: hyperparathyroidism, aluminum toxicity, osteomalacia and the more recently added dialysis-associated amyloidosis [1] . While the pathogenesis of the latter is currently under study, important progress has been achieved in the treatment and prevention of the other three in the last few years. Serum phosphate control can be obtained without the use of Al-containing phosphate binders and new vitamin D derivatives with different efficacy, administration techniques and side effects are available or under pre-clinical experimentation [2] [3] [4] . However, the new trends in the treatment of hyperparathyroidism generate different problems which require modifications of the classical approach to dialysis therapy [5] . One of the limiting factors in the use of high doses of CaCO3 in phosphate control is that of hypercalcemia. To avoid hypercalcemia a reduction in the dialysate Ca content (dCa) has been proposed [6] .
In the present study we wanted to compare the intrasession Ca kinetics in hemodialysis and our previously-described online hemodiafiltration system [7] using three different dCa concentrations. Besides the acute clinical consequences secondary to the lowering of dCa, long-term results were examined in a 12 month prospective protocol. Our results show that lowering dCa to 1.25 mri is safe from the point of view of potential hypocalcemia, intradialytic events and blood pressure control. However, a 2.8-fold increase in oral calcium intake with subsequent normalization of serum Ca levels was not sufficient to prevent stimulation of PTH secretion, as compared to a control group maintained with 1.5 mrt dCa. High doses of i.v. liz vitamin D3 can be given to both 1.5 and 1.25 ma't dCa treated patients with identical good results in decreasing PTH. Methods Calcium kinetics and intradialytic studies Patients. Seven men and two women with stable end-stable renal failure gave their consent to participate in the trial. Their mean age was 53.2 4 years old (range: 31 to 72) and they had been on kidney replacement therapy for 5.8 1.7 years. Their kidney diseases included chronic glomerulonephritis (3), chronic urinary tract infection (2) , Henoch-Schonlein syndrome (1), Wegener's disease (1) , and undetermined (2) . One patient was receiving labetalol as the antihypertensive treatment.
Kidney replacement techniques. This group of patients was routinely treated with post-dilutional hemodiafiltration (HDF) for three hours each, three times weekly with A-2008-C Fresenius machines and HF8O polysulfone membranes (Fresenius AG, Bad Homburg, Germany). Blood flow was maintained between 350 and 380 mllmin. Sterile, bicarbonate buffered infusate was produced by on-line filtration of ultrapure dialysate as previously described [7] . Ion contents were: Na 139 mM, K 1.5 m, Mg 0.5 mM, Cl 108 mM, HC03 36 m, and the Ca content was decreased from 1.75 to 1.5 and 1.25 mM. A total convective volume removal of 18 to 20 liters was used with 500 ml/min dialysate flow. Weight was monitored with Gambro weigh beds (Gambro, Lund Sweden), and blood pressure was measured with a Dinamap 8103 (Critikon, Creteil, France). Dialysis dose was controlled by urea kinetics measurements every month according to Farrel's method [81 as detailed elsewhere [9] ; a Kr/V > 1.4 with a PCR> 1 was sought.
Simple hemodialysis (HD) without the convective part of HDF but using the same dialysis parameters as above was performed in all patients, with the three dCa concentrations to analyze the differences between HD and HDF.
Parameters. iCa, Na and K were measured with specific electrodes (Fresenius EH-F lonometer; the intra-assay and interassay variability was <0.1% and <1%, respectively) in blood taken from the arterial and venous sides of the blood circuit, as well as in the dialysate taken from the outlet of the dialyzer, at the start, one hour, two hours, and at the end of the three-hour dialysis session. Total Ca (tCa) was manually determined by fluorometric measurement of calcein reaction with an intra-assay and interassay variability <1%. At the same time phosphate, total protein and bicarbonate were measured with a Kone autoanalyzer (KONE mc, Finland).
Protocol of calcium kinetics assessment. The patients were maintained on 1.75 dCa for more than three months, then Ca kinetics were assessed in three consecutive sessions (twice using HDF and a last one with isolated HD). Urea kinetic assessment was performed the consecutive week and the dCa changed to 1.5 m the week after, with assessment of Ca kinetics in the same way (3 consecutive sessions: 2 HDF and 1 isolated HD) 12 weeks after decreasing dCa to 1.5 mM. Identical assessment was carried out when the patients were changed from 1.5 to 1.25 mrvi dCa.
Blood pressure and dialysis tolerance. Intradialytic blood pressure, pulse and weight were recorded before, one hour, two hours, and at the end of the dialysis session. Intrasession events were recorded during a one month period while the patient was treated with the three different dCa concentrations. The results are expressed as events per 100 dialysis sessions.
Long-term effects of using 1.25 m'i dCa Patients. One patient was transplanted and another was transferred to another center shortly after the acute study of the 1.25 mri dCa. The long-term effects of lowering the dCa from 1.5 to 1.25 m were therefore assessed over a one year period in the remaining seven patients as well as in a control group of six patients maintained with 1.5 mri dCa throughout the study.
Biological parameters. Ca, phosphate and ALP were assessed pre-dialysis monthly. Osteocalcin and intact parathyroid hormone (iPTH) were assessed quarterly by RIA (Incstar Co, Stillwater, Minnesota, USA and Nichols Institute, San Juan Capistrano, California, USA). The variability for these tests was 3.4% and 5.6% intra-and interassay, respectively. Phosphate binders and oral vitamin D derivative doses were adapted to maintain tCa in the higher zone of the normal range (2.5 to 2.7 mM) and serum phosphate lower than 1.7 mM.
Blood pressure. Interdialytic systolic and diastolic blood pressures as well as heart rate were monitored for 24 hours with a SpaceLabs 90207-31 blood pressure monitor (SpaceLabs Inc., Redmond, Washington, USA) during the use of 1.5 and 1.25 mM dCa in the study group. There was more than 35 readings per record. The mean of the one day record was used as the blood pressure for a given patient and used for analysis.
High dose 1 a(OH) vitamin D3
Patients. The seven patients maintained with 1.25 dCa for more than one year, and a control group (also N = 7) with equivalent PTH serum levels and maintained with 1.5 dCa throughout the study were included in the protocol. Oral 1 a(OH) vitamin D3 was stopped and replaced by i.v. 1 a(OH) vitamin D3. One patient in each group did not tolerate i.v. la(OH) vitamin D3, and the analysis was performed in the remaining 12 patients separated into two groups according to dCa concentration (6 patients treated with 1.5 and 6 treated with 1.25 mM dCa).
Protocol. la(OH) vitamin D3 (Etalpha, Leo Laboratories, Denmark) was administered i.v. at the end of the dialysis session. The initial dose was 1 .tg (x3/week) which was increased stepwise weekly by I g until a total dose between 6 to 9 gIweek was given. iCa, tCa, phosphate and ALP were assessed weekly. The la(OH) vitamin D3 doses were adapted according to the predialysis serum iCa levels with the aim of maintaining pre-dialysis iCa levels of 2.5 to 2.7 mrvi. Intact PTH and osteocalcin serum levels were assessed monthly. This study was conducted for four months at the end of the one year follow-up with varied dCa.
Statistics
The Statistical Analysis System package (S.A.S., 1984, Cary, North Carolina, USA) was used. Comparison between two or three groups with several data points each, on a longitudinal basis, was performed with the analysis of the variance using Fisher's F value. This applied for intrasession kinetics and blood pressure studies (3 different groups with 4 data points each) and long-term assessment of lowering dCa (2 groups with 12 data points) and subsequent treatment with la(OH) vitamin D3 (2 groups with 4 data points). Longitudinal differences between two given data points were compared with the Student's t-test (normally distributed values) or with Wilcoxon's test for paired data (not Gaussian distributions). Correlations between numeric variables were tested with Pearson's r value and regression analysis was performed when appropriate. The values are given as mean standard error of the mean and a P <0.05 is considered to be statistically significant.
Results

Intradialysis studies
Ca and phosphate kinetics. The changes in iCa in the course of HDF for the three dialysate concentrations are shown in 0.0001); with 1.25 mt dCa it was small (0.06 0.008 mmollliter) and altered little during the course of the dialysis, while with 1.75 and 1.5 mi dCa it was higher and tended to decrease (Fig.   1C ).
The sieving of iCa [dialysate outlet (Do)Iblood inlet (Bill was significantly different in HDF when compared to HD alone (F = 6.73; P <0.01); however, this was compensated in HDF by the infusion of 18 liters containing the same Ca concentration of the dialysate. Thus, the iCa at the blood inlet did not differ significantly between HD and HDF (F = 2.59; NS). The intradialysis kinetics of iCa followed the same trend in HD and HDF except for the sieving of iCa (Fig. 2) .
The serum phosphate levels (blood inlet and outlet) were not significantly different as the dCa was lowered (F = 1.5; NS) ( Fig. 3 ). As expected, the reduction in serum phosphate in the course of dialysis was dependent on the initial serum phosphate level (Pearson's, r = 0.83; P < 0.0001). However, this reduction also correlated with HC03 (r = 0.53; P < 0.0001), but the 2). It can be observed that the dialysis dose given to these patients is largely greater than that advised by the NCDS study [10] , and it was similar in both groups.
Medications. The treatment with CaCO3 and la(OH) vitamin D3 are represented in Figure 5 . It can be seen that there was a 2.8-fold increase in the amount of CaCO3 taken while the study progressed after dCa was lowered to 1.25 m. After a one year follow-up, the dose of CaCO3 administered was 12.6 1 and 6.57 1.9 g/day/patient in the groups treated with 1.25 and 1.5 mM dCa, respectively. At the same time Al(OH)3 was completely withdrawn in both groups. Oral 1 a(OH) vitamin D3 remained stable during the follow-up period (the extreme values were 1 and 0.86 p,glweek/patient for the study group and 0.96 and 0.67 pg/week/patient for the control group).
Blood pressure report. None of the patients included in the low dCa group was receiving antihypertensive drugs. The 24 -hour blood pressure records are detailed in Table 3 . Systolic blood pressure was unchanged while decreasing dCa from 1.5 m to 1.25 m. By contrast, diastolic blood pressure and heart rate decreased significantly when the patients were switched to 1.25 mrvi dCa (Wilcoxon test P < 0.0469 and P < 0.0313, respectively).
Biochemistry. No significant variations were observed in tCa, phosphate and ALP ( Fig. 6A, B , and C). tCa was stable during the one year period (F = 0.9; NS) with values which ranged from 2.38 to 2.53, and was similar in both groups (F = 0.01; NS). Phosphate was also stable (F = 0.49; NS) and similar in both groups (F = 2.78; NS), ranging from 1.5 to 1.89 mmol/liter. Alkaline phosphatases showed opposite trends in the two groups: while the patients treated with dCa = 1.25 m increased ALP the patients with dCa = 1.5 m decreased their ALP serum levels. However, Wilcoxon's test for paired data was not significant for either group. Similarly, the analysis of the variance did not show statistical differences between the groups (F = 0.21; NS) or over the time of the study period (F = 0.01; NS).
Concerning iPTH values, although initially similar, they showed a significant increase in the study group over the year (Wilcoxon test; P < 0.047), while the control group remained very stable (Fig. 6D ). As a consequence iPTH was statistically different in both groups (F = 4.76; P < 0.036).
High dose of i.v. la(OH) vitamin D3 High dose i.v. la(OH) vitamin D3 was effective in lowering iPTH regardless of the dCa. As shown in Figure 7 , after four months of treatment, iPTH clearly decreased in both the group maintained with dCa = 1.5 and the group switched to dCa = clinical significance of this is uncertain. A weak but significant correlation between the serum phosphate level and iCa sieving (Do/Bi) was observed(r = 0.3 15; P <0.0001). However, it must be pointed out that although the phosphate levels did not alter significantly in the course of the study, the amount of phosphate binders taken by the patients increased (see below), and thus definite conclusions regarding the interrelationship of the serum phosphate and the dCa are difficult to draw.
Blood pressure and dialysis tolerance. Figure 4 shows intradialytic changes in systolic and diastolic blood pressure as well as heart rate during HDF with the three different dCa. A decrease in both SBP and DBP during the session was observed which was reversed with fluid restitution at the end of the dialysis. The heart rate decreased after the start of the session and started to increase from the second hour to compensate for the weight loss. The same patterns were observed with the three different dCa concentrations. DBP significantly decreased when lowering dCa to 1.25 mrvi (F = 4.6; P < 0.01). In contrast, decreasing dCa had no effect on SBP (F = 2.5; NS).
The intradialytic events most frequently recorded were hypotension, cramps and headache. As it can be seen in Table 1 , the average occurrence of intradialytic events was very low: 10 hypotensive episodes, 2.2 cramps and 1.7 headaches per 100 dialysis sessions, respectively. Although headaches disappeared with dCa = 1.25 m, because of the very low occurrence, the clinical relevance of these variations is not clear.
Long-term effects of using 1.25 m dCa Dialysis dose. The dialysis characteristics and delivered dose as measured by urea kinetic modeling were stable throughout the follow-up period in both the study and control group (Table   E   a) in ca pg/liter, respectively, in the months).
The evolution of tCa, phosphate and ALP is presented in Table 4 . There was a significant increase in tCa in the dCa 1.25 group (P < 0.05). The ALP tended to increase in both groups (17.3% and 10% in dCa 1.25 and dCa = 1.5 mM groups, respectively); however, this increase was not significant.
Discussion
From the studies by Slatopoisky and co-workers it has been known that control of the serum phosphate level is of great importance in the treatment and prevention of hyperparathy-study and control groups after 4 E E a. 0 The values given are the absolute number of events and in brackets events per 100 dialysis sessions. roidism [11] . Recently, new phosphate intestinal binders have been proposed to replace Al(OH)3 because of the latter's well-recognized toxicity [12, 13] . Although Ca acetate may be [6, [15] [16] [17] . Such an approach has also been previously reported as successful in treating acute malignant hypercalcemia and hypertension [18] . However, concerning the intradialysis Ca kinetics and balance, a single study has been recently reported by Hou et al [19] assessing tCa balance from the dialysate in HD with low dCa [19] .
With the technical progress achieved in the hemodialysis field, new dialysis membranes and techniques have become more commonly used [20] . We have recently reported the results of hemodiafiltration treatment on cardiovascular parameters and the clearances of small and large molecules [21] . However, no previous studies assessing the intrasession iCa kinetics in HD and the possible differences in HDF have been reported. Similarly, the long-term effects of lowering dCa have not been studied in HDF. In the present study, we assessed the intrasession kinetics for iCa and phosphate both during HD and HDF in the same patients, using three different dCa concentrations. We also studied the long-term effects of low dCa (1.25 mM) on blood pressure and hyperparathyroidism, and observed an increase in intact PTH levels which was not present in a group of patients maintained with 1.5 m dCa. We then treated the patients with high dose of i.v. la(OH) vitamin D3 and obtained an equally satisfactory correction of the iPTH levels in both groups of patients.
Concerning the study of the intradialytic Ca kinetics, we observed a clear increase in iCa during the sessions using 1.75 mM dCa which was still significant with 1.5 msi dCa. These intradialytic positive Ca variations were not observed with 1.25 mM dCa. These findings are consistent with the dialysate collection studies reported by Hou et al [19] . Comparing the kinetics in HD and HDF, we observed a significantly higher sieving for iCa in HDF which shows that Ca transfers through the dialyzer are different in HD and HDF. In HDF between 15 and 20 liters of plasma water are filtered during the treatment. This convective component results in an increased clearance which is more prominent for high molecular weight compounds but is also observed in small molecules [21] . Thus, the added convection results in an increased Ca loss which is compen-sated by the infusion of equal amounts of ultrafiltered dialysate (containing the same Ca concentration as the dialysate). As a consequence the iCa in the blood taken from the blood inlet was similar in HDF versus HD. Confirming this, Malberti and Surian [22] observed a significant decrease in Ca when performing HDF with Ca free infusate. Goldsmith et al in 1974 [23] studied the Ca flux during hemodialysis and showed that there is a significant correlation between serum phosphate levels and Ca transfer from the dialysate to the blood. Although in our study we found this correlation as well, its r value was relatively small (0.31).
It is known that iCa is a determinant of the blood pressure [24, 25] . It is positively inotropic [26] and also controls arterial smooth muscle contraction, modulating peripheral vascular resistances [27] . It has been previously shown that increasing iCa serum levels during dialysis result in an increase in mean arterial pressure [28] . However, while small blood pressure modifications during dialysis are statistically significant, they are frequently clinically irrelevant [29] . In our study, decreasing dCa to 1.25 m induced a minor but statistically significant decrease in diastolic blood pressure but no modifications of the systolic blood pressure. It has been demonstrated that the iCa actions to increase cardiac output and to increase systemic vascular resistance are distinguishable by the range of the iCa level. While an increase from low iCa to normal induces predominantly cardiac modifications, a further increase from normal to high iCa results in an increase in systemic vascular resistances [30] . These results are in keeping with our data since none of the patients included in this study was hypocalcemic and we found a significant decrease in DBP and no modification on SBP. These modifications did not translate into an impaired cardiovascular tolerance and the ultrafiltration rate was able to be maintained at the same level with no increase in body weight.
It is interesting to note that the modifications in blood pressure observed intradialytically were also found in the long-term study by monitoring the blood pressure for 24 hours.
Again the mean of the one day record showed a significant difference in DBP and heart rate, but not in SBP. Although it is always satisfying to control DBP, whether this minor drop in blood pressure is relevant for the patient in the long-term remains to be demonstrated.
Previous reports have analyzed the benefits of using the low dCa in association with CaCO3 to control serum phosphate levels and avoid hypercalcemia [6, 15, 16] . Mactier et al [15] and Sawyer et al [16] modified dCa from patient to patient according to serum Ca levels with a dCa ranging from 1.75 to 1.05 m, and analyzed the modifications after four months of using CaCO3. While Sawyer et al [16] found a significant decrease in intact PTH, Mactier et al [15] found a 22% increase in C-terminal PTH which did not reach statistical significance. In the study by Slatopolsky et al [6] the dCa was maintained constant at 1.25 m for seven months and iPTH decreased by 20%, but again the variation was not significant. The CaCO3 dose taken by our patients was higher than those used in these reports. However, despite obtaining a stable serum total Ca which was similar in both the 1.5 and 1.25 mM dCa group, iPTH increased significantly during the phase of 1.25 mM dCa treatment. This increase in iPTH was specific for the 1.25 dCa group, as it was not observed in the control group (dCa = 1.5), and appeared The means for the total values recorded per patient were calculated and taken as single value. The mean standard error of the mean of these values is given for the population's analysis, and Wilcoxon's test for paired data was applied to assess the differences. ap < 0.05 despite the stable Ca, phosphate and ALP serum levels. An acute decrease in iPTH levels has been reported during HD with 1.75 m dCa [311, and these authors have proposed this effect as a test to assess the ability to down-regulate the parathyroid gland. Other authors have confirmed this intradialytic decrease in PTH when a positive iCa balance is produced, and have shown that PTH inhibition is temporary as the predialysis level of PTH before the next treatment is unchanged [32, 33] . Although unlikely because the iPTH decrease is not protracted, it could be that the absence of such a periodic inhibition participated in the increase in iPTH we observed after one year treatment with 1.25 mM dCa.
There is increasing evidence showing that pulse therapy with vitamin D3 derivatives suppresses secondary hyperparathyroidism in dialysis patients [34] . The 1 ,25(OH)2 vitamin D3 form is the derivative most commonly reported. It has been used in oral [35] and i.v. therapy both in hemodialysis [34, 36] [40, 41] ; however, these authors reported an increase in serum Ca which was a limiting factor for the treatment, as they used dCa ranging from 1.5 to 1.8 mM.
Recently, Mornière et al [42] used i.v. la(OH) vitamin D3 in patients dialyzed with a dCa = 1.62 m, after discontinuing CaCO3. In this report the serum phosphate control with Mg(OH)2 was rather unsatisfactory forcing a decrease in 1 a(OH) vitamin D3 doses and subsequent hyperparathyroidism relapse [42] . Since the patients included in our study were treated with lower dCa, we used i.v. la(OH) vitamin D3 without discontinuing CaCO3. To assess the effect of the dCa on the treatment with 1 a(OH) vitamin D3, we administered the same treatment in a control group dialyzed with 1.5 mri dCa. In both groups of patients i.v. la(OH) vitamin D3 was similarly effective in decreasing iPTH and the decrease (-70%) was equivalent to those previously reported [40, 41] . Serum Ca levels increased after i.v. la(OH) vitamin D3 treatment; however, they remained within an acceptable range. 1 a(OH) vitamin D3 i.v. therapy had to be momentarily discontinued only on two occasions in each group. This confirms that when the patients are treated with dCa of 1.5 mmM or lower, and have a satisfactory phosphate and Ca levels, high doses of i.v. la(OH) vitamin D3 can be safely used with no need for discontinuing CaCO3. In summary, the present study shows that low Ca dialysate can be used both in HD and HDF with no deleterious intradialytic events and no associated hypotensive episodes, provided that the infusion fluid in HDF is not Ca free. An increased Ca oral intake to control serum phosphate levels is allowed without inducing hypercalcemia since the positive intradialytic balance is avoided. Lowering dCa to 1.25 m results in a minor but statistically significant decrease in DBP which may be of some benefit for the patient in the long-term. However, despite an increased oral Ca intake and satisfactory serum phosphate control an increase in serum iPTH was observed with 1.25 mM dCa. High doses of i.v. la(OH) vitamin D3 were effective in reversing the iPTH increase. This latter treatment could be equally used in both groups, patients treated with 1. The values are given as the percentage of the pre-treatment level which has been taken as 100%, It can be seen that there is a significant decrease in PTH levels in both groups. New Zealand Society of Nephrology. The authors thank Marie Thomas for her help throughout the study, and the nursing staff of the AIDER for their continuing assistance in the management of the patients and protocol execution.
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